The FDA Just Scheduled the Most Consequential Peptide Meeting in Years
The FDA peptide reclassification process took its most significant step forward on Tuesday. On Tuesday, the FDA announced it will […]
Regulatory
FDA Approves Foundayo (Orforglipron) — First Oral GLP-1 for Weight Loss With No Food or Water Restrictions
The FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 receptor agonist for
FDA Approves Icotyde — First Targeted Oral Peptide for Psoriasis
The FDA approved Icotyde (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and
FDA Sharpens Enforcement on Compounded GLP-1 Drugs as Shortage Era Ends
The FDA has publicly signaled its intent to take enforcement action against non-approved GLP-1 drugs — a shift that follows the
HHS Announces Peptide Reclassification — 14 Compounds Returning to Legal Compounding
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed
Wegovy Pill Launches — Oral Semaglutide Now Available for Weight Management
Novo Nordisk’s Wegovy pill — oral semaglutide at 25 mg, once daily — became commercially available in January 2026, following FDA approval in